Fierce Biotech Mix Logo.png Fierce Biotech Mix Logo.png
Webinar

Glycoproteomic Biomarkers in the Clinic: Developing Predictive Biomarkers for Therapeutic Response

Available on-demand
60 Minutes
The search for biomarkers for therapeutic response using traditional genomic sequencing and other omic approaches has often not yielded clinically actionable tools for most patients.
 
Join us for this insightful discussion on the biological importance of glycosylation and a deep dive into the latest targeted glycoproteomic solutions that are powering new clinical insights. We’ll take an exciting look at a recent clinical case study and discuss how glycoproteomic analysis can yield powerful prognostic and predictive biomarkers.
 
Topics will include:
  • The post-translational attachment of glycans to proteins, a distinct layer of omics not captured with traditional proteomics
  • Glycoproteomic biomarkers that have the potential to play a crucial role in early intervention and personalized therapy decisions
  • Innovations for generating clinically relevant insights through the glycoproteome
  • And more

Speakers

Intervenn-HS-David-2272025.png

Dr. David Braun

David Braun, MD, PhD, is an Assistant Professor of Medicine (Medical Oncology) and a member of the Center of Molecular and Cellular Oncology (CMCO) at Yale Cancer Center. Dr. Braun cares for patients with kidney cancers. He received his PhD in Computational Biology from the Courant Institute of Mathematical Science at New York University and his medical degree from Icahn School of Medicine at Mount Sinai. He completed his residency at the Brigham and Women’s Hospital where he received the Dunn Medical Intern Award and served as Chief Medical Resident before completing fellowship training in adult oncology through the Dana-Farber/Partners CancerCare program where he was appointed the Emil Frei Fellow and the John R. Svenson Fellow.

Dan Serie.jpeg

Dan Serie, M.S.

Dan is the Chief Data Officer at InterVenn, with over 15 years of experience mining the genome and proteome for biological and clinical insights. He holds a Bachelor of Science degree in Mathematics from the University of Minnesota and a Master's in Applied Statistics from Penn State. His team continues development on advanced machine learning techniques for detecting, quantifying, and utilizing glycoproteins, in service of the ultimate goal: moving these novel biomarkers into clinical practice and improving patient outcomes.

Intervenn-HS-Alex-2272025.png

Alex Vanotti, MBA

Alex is the Director of Product at InterVenn, with over 15 years of experience helping life science companies deliver innovative products to patients, including time at Genentech, Illumina, and Amazon prior to InterVenn.  Alex has a Bachelor of Science in Chemical Engineering from Clemson University, and an MBA from Duke University. 

Register here to watch on-demand!

Duration:
60 Minutes